Results 191 to 200 of about 7,490 (233)

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765)

Leukemia & Lymphoma, 2013
Over the past 3 years, ibrutinib (PCI-32765) has emerged as a breakthrough in targeted therapy for patients with certain types of B cell malignancies. Early stage clinical trials found ibrutinib to be particularly active in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), providing the rationale for ongoing phase 3 trials. In contrast
Jan A, Burger, Joseph J, Buggy
openaire   +2 more sources

Bruton's Tyrosine Kinase (Btk)

2012
Bruton's tyrosine kinase (Btk) is a non-receptor tyrosine kinase belonging to the Tec family of kinases. Btk is critical for B-cell development, differentiation and signalling through the B-cell antigen receptor (BCR) as is evident by its genetic association to a human primary immunodeficiency disease known as X-linked Agammaglobulinemia (XLA).
MARK E. SCHNUTE, ADRIAN HUANG, EDDINE SAIAH   +2 more
openaire   +1 more source

Cardiovascular Toxicities of Bruton’s Tyrosine Kinase Inhibitors

Current Treatment Options in Oncology, 2020
There has been a significant shift in the management of B cell malignancies over the past decade. Initial strategies involving the use of systemic chemotherapies have been gradually replaced by more targeted therapies to improve survival and overall tolerability.
Ricardo, Pineda-Gayoso, Mohammed, Alomar, Dae Hyun, Lee, Michael G, Fradley   +3 more
openaire   +2 more sources

Role of Bruton's tyrosine kinase in immunodeficiency

Current Opinion in Immunology, 1994
The genetic defect associated with human X-linked agammaglobulinemia and murine X-linked immunodeficiency was recently shown to result from lack of function of a new cytoplasmic tyrosine kinase, called Bruton's tyrosine kinase (Btk). The phenotypes associated with these immunodeficiencies indicate that Btk plays a critical role in B-lymphocyte ...
S, Tsukada, D J, Rawlings, O N, Witte
openaire   +2 more sources

Bruton tyrosine kinase (Btk) suppresses osteoblastic differentiation

Journal of Bone and Mineral Metabolism, 2014
The Tec family of nonreceptor tyrosine kinases has been shown to play a key role in inflammation and bone destruction. Bruton tyrosine kinase (Btk) has been the most widely studied because of its critical role in B cells. Furthermore, recent evidence has demonstrated that blocking Btk signaling is effective in ameliorating lymphoma progression and ...
Shoichi, Kaneshiro, Kosuke, Ebina, Kenrin, Shi, Kiyoshi, Yoshida, Dai, Otsuki, Hideki, Yoshikawa, Chikahisa, Higuchi   +6 more
openaire   +2 more sources

Bruton’s tyrosine kinase (Btk)—the critical tyrosine kinase in LPS signalling?

Immunology Letters, 2004
The discovery of the Toll-like receptors (TLRs) has revolutionised the field of innate immunity. One unresolved question regarding LPS signalling is whether there is a role for tyrosine kinases downstream of the LPS receptor. Studies in mice deficient in Bruton's tyrosine kinase have previously shown that they are defective in their responses to LPS ...
Caroline A, Jefferies, Luke A J, O'Neill
openaire   +2 more sources

X-Linked Agammaglobulinemia and Bruton’s Tyrosine Kinase

1994
The genetic defect associated with human X-linked agammaglobulinemia (XLA) and murine X-linked immunodeficiency (XID) was recently identified as the deficiency of function of a new cytoplasmic tyrosine kinase called Bruton’s tyrosine kinase (Btk)1,2,3,4. The phenotypes associated with these immunodeficiencies indicate that Btk plays a crucial role in B
S, Tsukada, O N, Witte
openaire   +2 more sources

Mutations in Bruton’s tyrosine kinase impair IgA responses

International Journal of Hematology, 2015
X-linked agammaglobulinemia (XLA) is a primary immunodeficiency caused by mutations in Bruton's tyrosine kinase (BTK), and is characterized by markedly decreased numbers of blood B cells and an absence of all immunoglobulin isotypes. We performed whole exome sequencing in a male pediatric patient with dysgammaglobulinemia with IgA deficiency.
Mitsuiki, N, Yang, X, Bartol, Benjamin, Grosserichter - Wagener, Christina, Kosaka, Y, Takada, H, Imai, K, Kanegane, H, Mizutani, S, van der Burg, Mirjam, van Zelm, Menno, Ohara, O, Morio, T   +12 more
openaire   +2 more sources

Clinical Potential of Targeting Bruton's Tyrosine Kinase

International Reviews of Immunology, 2008
Targeting Bruton's tyrosine kinase (BTK) with a small-molecule inhibitor may be useful in treatment of BTK-expressing malignancies because of the antiapoptotic function of BTK in cancer cells. Furthermore, BTK inhibitors also exhibit antithrombotic properties, which may be desirable in the context of the increased risk of thromboembolic complications ...
openaire   +2 more sources

Brutons Tyrosine Kinase as a New Therapeutic Target

Anti-Cancer Agents in Medicinal Chemistry, 2007
Targeting Brutons tyrosine kinase (BTK) with a small molecule inhibitor may be useful in treatment of BTK-expressing malignancies because of the anti-apoptotic function of BTK in cancer cells. Furthermore, BTK inhibitors also exhibit anti-thrombotic properties that may be desirable in the context of the increased risk of thromboembolic ...
Fatih M, Uckun, Heather E, Tibbles, Alexei O, Vassilev   +2 more
openaire   +2 more sources